C Lee
John Wiley & Sons
3e druk, 2014
9781118398241
Textbook of Hemophilia 3e
Specificaties
Gebonden, 560 blz.
|
Engels
John Wiley & Sons |
3e druk, 2014
ISBN13: 9781118398241
Rubricering
Levertijd ongeveer 15 werkdagen
Samenvatting
Textbook of Hemophilia, 3 rd edition Edited by Christine A. Lee, MA, MD, DSc, FRCP, FRCPath, FRCOG Emeritus Professor of Haemophilia, University of London, London, UK Erik E. Berntorp, MD, PhD Professor of Coagulation Medicine, Lund University Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden W. Keith Hoots, MD Director, Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD; Professor of Pediatrics and Internal Medicine, University of Texas Medical School at Houston, Houston, TX, USA Without doubt, Textbook of Hemophilia, 3 rd edition is the definitive reference source on all aspects of haemophilia including diagnosis, management and treatment. Edited by three, world–renowned experts on haemophilia, this completely revised resource features chapters written by over 60 international contributors with international expertise in caring for haemophilia patients. Textbook of Hemophilia, 3 rd edition Features eight new chapters, covering individualised dosing, vCJD and haemophilia, new drugs in the pipeline, and surgery in inhibitor patients Presents new developments, such as gene therapy Highlights controversial issues and provides advice for everyday clinical questions Represents essential reading for all healthcare professionals involved in the care of those with haemophilia Titles of related interest Hemophilia and Hemostasis: A Case–Based Approach to Management, 2nd Edition Ma , ISBN: 9780470659762 Current and Future Issues in Hemophilia Care Rodriguez–Merchan , ISBN: 9780470670576 www.wiley.com/go/hematology
Specificaties
ISBN13:9781118398241
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:560
Uitgever:John Wiley & Sons
Druk:3
Inhoudsopgave
<p>Contributors, ix</p>
<p>Historical introduction, xv<br /> Christine A. Lee</p>
<p>PART I: Introduction</p>
<p>1 Overview of hemostasis, 3<br /> Kathleen Brummel Ziedins and Kenneth G. Mann</p>
<p>2 Cellular processing of factor VIII and factor IX, 9<br /> Michael U. Callaghan and Randal J. Kaufman</p>
<p>PART II: Hemophilia A</p>
<p>3 Molecular basis of hemophilia A, 23<br /> Geoffrey Kemball–Cook and Keith Gomez</p>
<p>4 Prophylaxis, 33<br /> Kathelijn Fischer and H. Marijke van den Berg</p>
<p>PART III: Inhibitors to factor VIII</p>
<p>5 Inhibitors to factor VIII: immunology, 43<br /> Jean–Marie R. Saint–Remy and Marc G. Jacquemin</p>
<p>6 Genetic and environmental risk factors for factor VIII inhibitor development, 48<br /> Jan Astermark</p>
<p>7 Epidemiology of inhibitors in hemophilia, 53<br /> Alfonso Iorio</p>
<p>8 Inhibitors to factor VIII: mild and moderate hemophilia, 59<br /> Kathelijne Peerlinck and Marc Jacquemin</p>
<p>9 Inhibitors to factor VIII/IX: immune tolerance, 64<br /> Donna M. DiMichele</p>
<p>10 Prophylaxis in inhibitor patients, 72<br /> Alessandro Gringeri</p>
<p>11 Inhibitors to factor VIII: treatment of acute bleeds, 78<br /> Claude Negrier</p>
<p>PART IV: Acquired hemophilia</p>
<p>12 Acquired inhibitors to factor VIII, 87<br /> Craig M. Kessler</p>
<p>PART V: Hemophilia B</p>
<p>13 Hemophilia B: molecular basis, 97<br /> Keith Gomez and Pratima Chowdary</p>
<p>14 Factor IX inhibitors in hemophilia B, 103<br /> Meera B. Chitlur and Jeanne M. Lusher</p>
<p>15 Treatment of inhibitors in hemophilia B, 107<br /> Anand Tandra and Amy D. Shapiro</p>
<p>PART VI: Pharmacokinetics of factors VIII and IX</p>
<p>16 Pharmacokinetics, 117<br /> Sven Björkman</p>
<p>17 Individualized dosing, 123<br /> Peter W. Collins</p>
<p>PART VII: Hemophilia: birth to old age</p>
<p>18 Neonate with hemophilia, 131<br /> Angela E. Thomas and Elizabeth A. Chalmers</p>
<p>19 Work–up of a bleeding child, 138<br /> Manuel D. Carcao and Victor S. Blanchette</p>
<p>20 Care of the child with hemophilia, 145<br /> Rolf C.R. Ljung</p>
<p>21 Hemophilia in adolescence, 150<br /> Pia Petrini</p>
<p>22 Old age medicine and hemophilia, 154<br /> Evelien P. Mauser–Bunschoten and Roger E.G. Schutgens</p>
<p>PART VIII: Products used to treat hemophilia</p>
<p>23 Products used to treat hemophilia: recombinant products, 165<br /> Midori Shima and Akira Yoshioka</p>
<p>24 Products used to treat hemophilia: plasma–derived coagulation factor concentrates, 174<br /> Paul L.F. Giangrande</p>
<p>25 Products used to treat hemophilia: dosing, 180<br /> Miguel A. Escobar</p>
<p>26 Products used to treat hemophilia: regulation, 185<br /> Albert Farrugia</p>
<p>27 New drugs in the pipeline: from concept to clinic, 192<br /> Leonard A. Valentino</p>
<p>PART IX: Surgical management</p>
<p>28 General surgical management of patients with hemophilia, 199<br /> Cindy Leissinger and Rebecca Kruse–Jarres</p>
<p>29 Continuous infusion of coagulation products in hemophilia, 204<br /> Angelika Batorova and Uri Martinowitz</p>
<p>30 Surgery in inhibitor patients, 213<br /> Pål Andrè Holme</p>
<p>PART X: Musculoskeletal</p>
<p>31 Joint replacement in patients with hemophilia, 221<br /> Nicholas Goddard</p>
<p>32 Medical synovectomy (synoviorthesis) in hemophilia: radiosynovectomy and chemical synovectomy, 228<br /> E. Carlos Rodriguez–Merchan</p>
<p>33 Pseudotumors in patients with hemophilia, 233<br /> Michael Heim and Uri Martinowitz</p>
<p>34 Imaging modalities for assessment of hemophilic arthropathy, 237<br /> Andrea S. Doria and Björn Lundin</p>
<p>35 Physiotherapy in the management of hemophilia, 247<br /> Sébastien Lobet and David Stephensen</p>
<p>36 Outcome assessment in hemophilia, 253<br /> Pradeep M. Poonnoose and Alok Srivastava</p>
<p>PART XI: Transfusion–transmitted disease</p>
<p>37 Viral hepatitis and hemophilia, 265<br /> Michael Makris and Geoffrey Dusheiko</p>
<p>38 Transfusion–transmitted disease: emerging infections, 272<br /> Thomas R. Kreil</p>
<p>39 vCJD and hemophilia, 277<br /> Carolyn M. Millar</p>
<p>PART XII: Gene therapy</p>
<p>40 Hemophilia gene therapy: an overview, 285<br /> David Lillicrap</p>
<p>41 Gene therapy trials in hemophilia A and B, 291<br /> Katherine A. High</p>
<p>42 Gene therapy: molecular engineering of factor VIII and factor IX, 298<br /> Sundar R. Selvaraj and Steven W. Pipe</p>
<p>PART XIII: Laboratory</p>
<p>43 Laboratory and quality control of assays, 311<br /> Steve Kitchen</p>
<p>44 Standardization of assays in hemophilia, 318<br /> Sanj Raut and Trevor W. Barrowcliffe</p>
<p>45 Global laboratory assays in hemophilia, 328<br /> Benny Sørensen and Guy Young</p>
<p>PART XIV: Women and bleeding disorders</p>
<p>46 Obstetrics and gynecology: hemophilia, 337<br /> Rezan A. Kadir and Christine A. Lee</p>
<p>47 Women and von Willebrand disease, 345<br /> Peter A. Kouides</p>
<p>PART XV: von Willebrand disease</p>
<p>48 von Willebrand disease: molecular aspects, 355<br /> Daniel Hampshire and Anne Goodeve</p>
<p>49 von Willebrand disease: epidemiology, 362<br /> Francesco Rodeghiero and Giancarlo Castaman</p>
<p>50 von Willebrand disease: biological diagnosis, 370<br /> Veronica H. Flood and Robert R. Montgomery</p>
<p>51 Classification and clinical aspects of von Willebrand disease, 377<br /> Augusto B. Federici</p>
<p>52 Treatment of von Willebrand disease: desmopressin, 386<br /> Pier M. Mannucci</p>
<p>53 Treatment of von Willebrand disease: therapeutic concentrates, 390<br /> Erik E. Berntorp</p>
<p>PART XVI: Rare bleeding disorders</p>
<p>54 Factor II, 399<br /> Jan Astermark</p>
<p>55 Factor V and combined factor V and VIII deficiencies, 403<br /> Flora Peyvandi and Marzia Menegatti</p>
<p>56 Congenital factor VII deficiency, 413<br /> Angelika Batorova</p>
<p>57 Factor X and factor X deficiency, 421<br /> David J. Perry</p>
<p>58 Factor XI deficiency, 428<br /> Paula H.B. Bolton–Maggs and Uri Seligsohn</p>
<p>59 Factor XIII deficiency, 436<br /> Diane Nugent and Loan Hsieh</p>
<p>60 Fibrinogen deficiency, 445<br /> Michael Laffan</p>
<p>61 Miscellaneous rare bleeding disorders, 452<br /> Frederico Xavier and Amy D. Shapiro</p>
<p>PART XVII: Emergency medicine</p>
<p>62 Emergency management of hemophilia, 463<br /> W. Keith Hoots</p>
<p>PART XVIII: Evaluation of hemophilia</p>
<p>63 Clinical trials and other methodologies, 473<br /> Sharyne M. Donfield and Alice E. Lail</p>
<p>64 Quality of life in hemophilia, 478<br /> Sylvia von Mackensen and Alessandro Gringeri</p>
<p>65 The economics of hemophilia treatment, 489<br /> Katarina Steen Carlsson and Erik E. Berntorp</p>
<p>PART XIX: Comprehensive care and delivery of care</p>
<p>66 Hemophilia databases, 497<br /> Charles R.M. Hay</p>
<p>67 Comprehensive care and delivery of care: the developed world, 502<br /> Christopher A. Ludlam and Cedric R.J.R. Hermans</p>
<p>68 Comprehensive care and delivery of care in hemophilia: the developing world, 508<br /> Alok Srivastava and Auro Viswabandya</p>
<p>69 Comprehensive care and delivery of care: the global perspective, 515<br /> Mark W. Skinner and Alison M. Street</p>
<p>Index, 523</p>
<p>Color plate section can be found facing page 202</p>
<p>Historical introduction, xv<br /> Christine A. Lee</p>
<p>PART I: Introduction</p>
<p>1 Overview of hemostasis, 3<br /> Kathleen Brummel Ziedins and Kenneth G. Mann</p>
<p>2 Cellular processing of factor VIII and factor IX, 9<br /> Michael U. Callaghan and Randal J. Kaufman</p>
<p>PART II: Hemophilia A</p>
<p>3 Molecular basis of hemophilia A, 23<br /> Geoffrey Kemball–Cook and Keith Gomez</p>
<p>4 Prophylaxis, 33<br /> Kathelijn Fischer and H. Marijke van den Berg</p>
<p>PART III: Inhibitors to factor VIII</p>
<p>5 Inhibitors to factor VIII: immunology, 43<br /> Jean–Marie R. Saint–Remy and Marc G. Jacquemin</p>
<p>6 Genetic and environmental risk factors for factor VIII inhibitor development, 48<br /> Jan Astermark</p>
<p>7 Epidemiology of inhibitors in hemophilia, 53<br /> Alfonso Iorio</p>
<p>8 Inhibitors to factor VIII: mild and moderate hemophilia, 59<br /> Kathelijne Peerlinck and Marc Jacquemin</p>
<p>9 Inhibitors to factor VIII/IX: immune tolerance, 64<br /> Donna M. DiMichele</p>
<p>10 Prophylaxis in inhibitor patients, 72<br /> Alessandro Gringeri</p>
<p>11 Inhibitors to factor VIII: treatment of acute bleeds, 78<br /> Claude Negrier</p>
<p>PART IV: Acquired hemophilia</p>
<p>12 Acquired inhibitors to factor VIII, 87<br /> Craig M. Kessler</p>
<p>PART V: Hemophilia B</p>
<p>13 Hemophilia B: molecular basis, 97<br /> Keith Gomez and Pratima Chowdary</p>
<p>14 Factor IX inhibitors in hemophilia B, 103<br /> Meera B. Chitlur and Jeanne M. Lusher</p>
<p>15 Treatment of inhibitors in hemophilia B, 107<br /> Anand Tandra and Amy D. Shapiro</p>
<p>PART VI: Pharmacokinetics of factors VIII and IX</p>
<p>16 Pharmacokinetics, 117<br /> Sven Björkman</p>
<p>17 Individualized dosing, 123<br /> Peter W. Collins</p>
<p>PART VII: Hemophilia: birth to old age</p>
<p>18 Neonate with hemophilia, 131<br /> Angela E. Thomas and Elizabeth A. Chalmers</p>
<p>19 Work–up of a bleeding child, 138<br /> Manuel D. Carcao and Victor S. Blanchette</p>
<p>20 Care of the child with hemophilia, 145<br /> Rolf C.R. Ljung</p>
<p>21 Hemophilia in adolescence, 150<br /> Pia Petrini</p>
<p>22 Old age medicine and hemophilia, 154<br /> Evelien P. Mauser–Bunschoten and Roger E.G. Schutgens</p>
<p>PART VIII: Products used to treat hemophilia</p>
<p>23 Products used to treat hemophilia: recombinant products, 165<br /> Midori Shima and Akira Yoshioka</p>
<p>24 Products used to treat hemophilia: plasma–derived coagulation factor concentrates, 174<br /> Paul L.F. Giangrande</p>
<p>25 Products used to treat hemophilia: dosing, 180<br /> Miguel A. Escobar</p>
<p>26 Products used to treat hemophilia: regulation, 185<br /> Albert Farrugia</p>
<p>27 New drugs in the pipeline: from concept to clinic, 192<br /> Leonard A. Valentino</p>
<p>PART IX: Surgical management</p>
<p>28 General surgical management of patients with hemophilia, 199<br /> Cindy Leissinger and Rebecca Kruse–Jarres</p>
<p>29 Continuous infusion of coagulation products in hemophilia, 204<br /> Angelika Batorova and Uri Martinowitz</p>
<p>30 Surgery in inhibitor patients, 213<br /> Pål Andrè Holme</p>
<p>PART X: Musculoskeletal</p>
<p>31 Joint replacement in patients with hemophilia, 221<br /> Nicholas Goddard</p>
<p>32 Medical synovectomy (synoviorthesis) in hemophilia: radiosynovectomy and chemical synovectomy, 228<br /> E. Carlos Rodriguez–Merchan</p>
<p>33 Pseudotumors in patients with hemophilia, 233<br /> Michael Heim and Uri Martinowitz</p>
<p>34 Imaging modalities for assessment of hemophilic arthropathy, 237<br /> Andrea S. Doria and Björn Lundin</p>
<p>35 Physiotherapy in the management of hemophilia, 247<br /> Sébastien Lobet and David Stephensen</p>
<p>36 Outcome assessment in hemophilia, 253<br /> Pradeep M. Poonnoose and Alok Srivastava</p>
<p>PART XI: Transfusion–transmitted disease</p>
<p>37 Viral hepatitis and hemophilia, 265<br /> Michael Makris and Geoffrey Dusheiko</p>
<p>38 Transfusion–transmitted disease: emerging infections, 272<br /> Thomas R. Kreil</p>
<p>39 vCJD and hemophilia, 277<br /> Carolyn M. Millar</p>
<p>PART XII: Gene therapy</p>
<p>40 Hemophilia gene therapy: an overview, 285<br /> David Lillicrap</p>
<p>41 Gene therapy trials in hemophilia A and B, 291<br /> Katherine A. High</p>
<p>42 Gene therapy: molecular engineering of factor VIII and factor IX, 298<br /> Sundar R. Selvaraj and Steven W. Pipe</p>
<p>PART XIII: Laboratory</p>
<p>43 Laboratory and quality control of assays, 311<br /> Steve Kitchen</p>
<p>44 Standardization of assays in hemophilia, 318<br /> Sanj Raut and Trevor W. Barrowcliffe</p>
<p>45 Global laboratory assays in hemophilia, 328<br /> Benny Sørensen and Guy Young</p>
<p>PART XIV: Women and bleeding disorders</p>
<p>46 Obstetrics and gynecology: hemophilia, 337<br /> Rezan A. Kadir and Christine A. Lee</p>
<p>47 Women and von Willebrand disease, 345<br /> Peter A. Kouides</p>
<p>PART XV: von Willebrand disease</p>
<p>48 von Willebrand disease: molecular aspects, 355<br /> Daniel Hampshire and Anne Goodeve</p>
<p>49 von Willebrand disease: epidemiology, 362<br /> Francesco Rodeghiero and Giancarlo Castaman</p>
<p>50 von Willebrand disease: biological diagnosis, 370<br /> Veronica H. Flood and Robert R. Montgomery</p>
<p>51 Classification and clinical aspects of von Willebrand disease, 377<br /> Augusto B. Federici</p>
<p>52 Treatment of von Willebrand disease: desmopressin, 386<br /> Pier M. Mannucci</p>
<p>53 Treatment of von Willebrand disease: therapeutic concentrates, 390<br /> Erik E. Berntorp</p>
<p>PART XVI: Rare bleeding disorders</p>
<p>54 Factor II, 399<br /> Jan Astermark</p>
<p>55 Factor V and combined factor V and VIII deficiencies, 403<br /> Flora Peyvandi and Marzia Menegatti</p>
<p>56 Congenital factor VII deficiency, 413<br /> Angelika Batorova</p>
<p>57 Factor X and factor X deficiency, 421<br /> David J. Perry</p>
<p>58 Factor XI deficiency, 428<br /> Paula H.B. Bolton–Maggs and Uri Seligsohn</p>
<p>59 Factor XIII deficiency, 436<br /> Diane Nugent and Loan Hsieh</p>
<p>60 Fibrinogen deficiency, 445<br /> Michael Laffan</p>
<p>61 Miscellaneous rare bleeding disorders, 452<br /> Frederico Xavier and Amy D. Shapiro</p>
<p>PART XVII: Emergency medicine</p>
<p>62 Emergency management of hemophilia, 463<br /> W. Keith Hoots</p>
<p>PART XVIII: Evaluation of hemophilia</p>
<p>63 Clinical trials and other methodologies, 473<br /> Sharyne M. Donfield and Alice E. Lail</p>
<p>64 Quality of life in hemophilia, 478<br /> Sylvia von Mackensen and Alessandro Gringeri</p>
<p>65 The economics of hemophilia treatment, 489<br /> Katarina Steen Carlsson and Erik E. Berntorp</p>
<p>PART XIX: Comprehensive care and delivery of care</p>
<p>66 Hemophilia databases, 497<br /> Charles R.M. Hay</p>
<p>67 Comprehensive care and delivery of care: the developed world, 502<br /> Christopher A. Ludlam and Cedric R.J.R. Hermans</p>
<p>68 Comprehensive care and delivery of care in hemophilia: the developing world, 508<br /> Alok Srivastava and Auro Viswabandya</p>
<p>69 Comprehensive care and delivery of care: the global perspective, 515<br /> Mark W. Skinner and Alison M. Street</p>
<p>Index, 523</p>
<p>Color plate section can be found facing page 202</p>